Dolutegravir‐induced acquired sideroblastic anemia in a HIV positive patient: A challenging hematologic complication

Key Clinical Message Dolutegravir, the most recent antiretroviral drug with high efficacy, good tolerability, infrequent drug–drug interactions, and a favorable safety profile has not been reported in current literature as a cause of acquired sideroblastic anemia. Here, we present a 35‐year‐old male...

Full description

Saved in:
Bibliographic Details
Published in:Clinical case reports 2023-12, Vol.11 (12), p.e8301-n/a
Main Authors: Dhonju, Kiran, Gautam, Ashmita, Dahal, Abhinav, Sharma, Niraj Kumar, Adhikari, Divas, Devkota, Lina, Adhikari, Prabhat, Tuladhar, Sampurna, Pathak, Bishnu Deep, Banmala, Sabin
Format: Article
Language:English
Subjects:
acquired sideroblastic anemia
adverse drug reaction
Anemia
Biopsy
Bone marrow
Case Report
Congenital diseases
Dolutegravir
Drug dosages
Drug therapy
Hematology
HIV
Human immunodeficiency virus
Hyperplasia
Infectious Diseases
Iron
Mitochondria
Myelodysplastic syndromes
Naranjo scale
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Key Clinical Message Dolutegravir, the most recent antiretroviral drug with high efficacy, good tolerability, infrequent drug–drug interactions, and a favorable safety profile has not been reported in current literature as a cause of acquired sideroblastic anemia. Here, we present a 35‐year‐old male patient who was diagnosed with acquired sideroblastic anemia to Dolutegravir therapy.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.8301